Roche has refined the focus of this opportunity to specifically target patients who lack access to cellular therapies, rather than curative therapies in general. You will also find that measuring and reporting educational outcomes is now explicitly marked as encouraged but not required. Additionally, the guidelines clarify that there are no preferred providers, ensuring all submissions are reviewed equally.
Funder: Roche
Due Dates: May 15, 2026: Full application submission deadline (providers have 4 weeks to complete a full application; include “2026 DLBCL RFP” in program title)
Funding Amounts: Up to $150,000 per award; single-year funding; typical award expected to be less than or equal to this amount.
Summary: Supports independent medical education to improve care and knowledge for relapsed/refractory DLBCL, focusing on new therapies and care coordination for community-based healthcare teams.